卵巢癌是女性生殖系統(tǒng)最致命的惡性腫瘤。目前，針對(duì)卵巢癌的規(guī)范治療方案是腫瘤細(xì)胞減滅術(shù)輔以紫杉醇/鉑類聯(lián)合化療，然而大多數(shù)晚期卵巢癌患者最終因?qū)熕幬锬退幎鴱?fù)發(fā)。PI3K/AKT/mTOR信號(hào)通路作為一條重要的原癌基因通路，在卵巢癌中激活并在卵巢癌的增殖、侵襲、細(xì)胞周期進(jìn)程、血管形成及耐藥中發(fā)揮著重要的作用，抑制該通路是卵巢癌的一個(gè)潛在治療方法。對(duì)PI3K/AKT/mTOR信號(hào)通路抑制劑在卵巢癌治療中的研究進(jìn)展進(jìn)行綜述。

Ovarian cancer remains the leading cause of death in gynecologic malignancies. The current standard treatment for ovarian cancer includes radical surgery and platinum or taxane-based chemotherapy. However, most advanced ovarian cancer patients eventually relapse due to drug resistance to chemotherapy. As such, the search for more effective anti-ovarian cancer agents is urgent. The PI3K/AKT/mTOR pathway is thought to be one of the most important oncogenic pathways in human cancer. An increasing body of evidence has shown that this pathway is frequently hyperactivated in ovarian cancer and contributes to disease initiation and development, including proliferation, invasion, cell cycle progression, angiogenesis, and chemo-resistance. Inhibition of this pathway through small molecule compounds represents an attractive potential therapeutic approach for ovarian cancer. Therefore, research progress on PI3K/AKT/mTOR signaling pathway inhibitors in treatment of ovarian cancer is reviewed in this paper.

遼寧省卵巢癌惡性腫瘤病例信息平臺(tái)的建立及診治技術(shù)規(guī)范化推廣項(xiàng)目（LNCCC-A01-2015）；沈陽市科技計(jì)劃項(xiàng)目（17-230-9-10）；中國醫(yī)科大學(xué)2017年度學(xué)科提升計(jì)劃項(xiàng)目（2017CXTD05）；盛京自由研究者計(jì)劃項(xiàng)目（201704）